Role of IL-10 in the resolution of airway inflammation

Yoshiko Ogawa, Enrico A. Duru, Bill Ameredes

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

IL-10 can be considered an important agent in the resolution of inflammation. Originally named "cytokine synthesis inhibitory factor" for its ability to inhibit IFN-y and IL-2 production in Th2 cells, it is secreted by monocytes, macrophages, mast cells, T and B lymphocytes, and dendritic cells (DCs). IL-10 production and release by monocytic cells in response to allergic challenge is upregulated by TNF-α, and by negative feedback regulation of itself. However, it is also secreted by T regulatory cells (Tregs), under the control of IL-2. Importantly in the context of asthma, IL-10 inhibits eosinophilia, by suppression of IL-5 and GM-CSF, by direct effects on eosinophil apoptosis, and effects on cell proliferation through down-regulation of IL-1. A number of its cytokine suppressive characteristics are now thought to occur through its upregulation of suppressor of cytokine signaling (SOCS)-3. IL-10 is also a suppressor of nitric oxide (NO) production, which may have ramifications for its role in airway inflammatory diseases. Initial clinical trials have demonstrated relative safety and few clinically adverse events at doses of recombinant human IL-10 below 50 μg/kg, with mixed success in treatment of patients with inflammatory bowel disease and psoriasis. However, both steroid therapy and allergen specific immunotherapy are known to elevate endogenous IL-10 levels, which may account for their efficacy, suggesting that further study of IL-10 as a target for treatment of airway inflammatory diseases such as asthma and COPD is warranted.

Original languageEnglish (US)
Pages (from-to)437-445
Number of pages9
JournalCurrent Molecular Medicine
Volume8
Issue number5
DOIs
StatePublished - Aug 2008

Fingerprint

Interleukin-10
Inflammation
Interleukin-2
Asthma
Cytokines
Immunologic Desensitization
Th2 Cells
Lymphocytes
Macrophages
Interleukin-5
Cell proliferation
Eosinophilia
Regulatory T-Lymphocytes
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-1
Inflammatory Bowel Diseases
Psoriasis
Eosinophils
Mast Cells
Allergens

Keywords

  • Allergy
  • Antigen-presenting cells
  • Asthma
  • T regulatory cells

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine

Cite this

Role of IL-10 in the resolution of airway inflammation. / Ogawa, Yoshiko; Duru, Enrico A.; Ameredes, Bill.

In: Current Molecular Medicine, Vol. 8, No. 5, 08.2008, p. 437-445.

Research output: Contribution to journalArticle

Ogawa, Yoshiko ; Duru, Enrico A. ; Ameredes, Bill. / Role of IL-10 in the resolution of airway inflammation. In: Current Molecular Medicine. 2008 ; Vol. 8, No. 5. pp. 437-445.
@article{a5f6fb113a904ba39cfa83af30d01abf,
title = "Role of IL-10 in the resolution of airway inflammation",
abstract = "IL-10 can be considered an important agent in the resolution of inflammation. Originally named {"}cytokine synthesis inhibitory factor{"} for its ability to inhibit IFN-y and IL-2 production in Th2 cells, it is secreted by monocytes, macrophages, mast cells, T and B lymphocytes, and dendritic cells (DCs). IL-10 production and release by monocytic cells in response to allergic challenge is upregulated by TNF-α, and by negative feedback regulation of itself. However, it is also secreted by T regulatory cells (Tregs), under the control of IL-2. Importantly in the context of asthma, IL-10 inhibits eosinophilia, by suppression of IL-5 and GM-CSF, by direct effects on eosinophil apoptosis, and effects on cell proliferation through down-regulation of IL-1. A number of its cytokine suppressive characteristics are now thought to occur through its upregulation of suppressor of cytokine signaling (SOCS)-3. IL-10 is also a suppressor of nitric oxide (NO) production, which may have ramifications for its role in airway inflammatory diseases. Initial clinical trials have demonstrated relative safety and few clinically adverse events at doses of recombinant human IL-10 below 50 μg/kg, with mixed success in treatment of patients with inflammatory bowel disease and psoriasis. However, both steroid therapy and allergen specific immunotherapy are known to elevate endogenous IL-10 levels, which may account for their efficacy, suggesting that further study of IL-10 as a target for treatment of airway inflammatory diseases such as asthma and COPD is warranted.",
keywords = "Allergy, Antigen-presenting cells, Asthma, T regulatory cells",
author = "Yoshiko Ogawa and Duru, {Enrico A.} and Bill Ameredes",
year = "2008",
month = "8",
doi = "10.2174/156652408785160907",
language = "English (US)",
volume = "8",
pages = "437--445",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Role of IL-10 in the resolution of airway inflammation

AU - Ogawa, Yoshiko

AU - Duru, Enrico A.

AU - Ameredes, Bill

PY - 2008/8

Y1 - 2008/8

N2 - IL-10 can be considered an important agent in the resolution of inflammation. Originally named "cytokine synthesis inhibitory factor" for its ability to inhibit IFN-y and IL-2 production in Th2 cells, it is secreted by monocytes, macrophages, mast cells, T and B lymphocytes, and dendritic cells (DCs). IL-10 production and release by monocytic cells in response to allergic challenge is upregulated by TNF-α, and by negative feedback regulation of itself. However, it is also secreted by T regulatory cells (Tregs), under the control of IL-2. Importantly in the context of asthma, IL-10 inhibits eosinophilia, by suppression of IL-5 and GM-CSF, by direct effects on eosinophil apoptosis, and effects on cell proliferation through down-regulation of IL-1. A number of its cytokine suppressive characteristics are now thought to occur through its upregulation of suppressor of cytokine signaling (SOCS)-3. IL-10 is also a suppressor of nitric oxide (NO) production, which may have ramifications for its role in airway inflammatory diseases. Initial clinical trials have demonstrated relative safety and few clinically adverse events at doses of recombinant human IL-10 below 50 μg/kg, with mixed success in treatment of patients with inflammatory bowel disease and psoriasis. However, both steroid therapy and allergen specific immunotherapy are known to elevate endogenous IL-10 levels, which may account for their efficacy, suggesting that further study of IL-10 as a target for treatment of airway inflammatory diseases such as asthma and COPD is warranted.

AB - IL-10 can be considered an important agent in the resolution of inflammation. Originally named "cytokine synthesis inhibitory factor" for its ability to inhibit IFN-y and IL-2 production in Th2 cells, it is secreted by monocytes, macrophages, mast cells, T and B lymphocytes, and dendritic cells (DCs). IL-10 production and release by monocytic cells in response to allergic challenge is upregulated by TNF-α, and by negative feedback regulation of itself. However, it is also secreted by T regulatory cells (Tregs), under the control of IL-2. Importantly in the context of asthma, IL-10 inhibits eosinophilia, by suppression of IL-5 and GM-CSF, by direct effects on eosinophil apoptosis, and effects on cell proliferation through down-regulation of IL-1. A number of its cytokine suppressive characteristics are now thought to occur through its upregulation of suppressor of cytokine signaling (SOCS)-3. IL-10 is also a suppressor of nitric oxide (NO) production, which may have ramifications for its role in airway inflammatory diseases. Initial clinical trials have demonstrated relative safety and few clinically adverse events at doses of recombinant human IL-10 below 50 μg/kg, with mixed success in treatment of patients with inflammatory bowel disease and psoriasis. However, both steroid therapy and allergen specific immunotherapy are known to elevate endogenous IL-10 levels, which may account for their efficacy, suggesting that further study of IL-10 as a target for treatment of airway inflammatory diseases such as asthma and COPD is warranted.

KW - Allergy

KW - Antigen-presenting cells

KW - Asthma

KW - T regulatory cells

UR - http://www.scopus.com/inward/record.url?scp=53849116091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53849116091&partnerID=8YFLogxK

U2 - 10.2174/156652408785160907

DO - 10.2174/156652408785160907

M3 - Article

C2 - 18691071

AN - SCOPUS:53849116091

VL - 8

SP - 437

EP - 445

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 5

ER -